Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised,open-label,non-inferiority,phase 3 TURANDOT trial期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised,open-label,non-inferiority,phase 3 TURANDOT trial

Authors:	Istvan Lang Thomas Brodowicz Larisa Ryvo Zsuzsanna Kahan Richard Greil Semir Beslija Salomon M Stemmer Bella Kaufman Zanete Zvirbule Günther G Steger Bohuslav Melichar Tadeusz Pienkowski Daniela Sirbu Diethelm Messinger Christoph Zielinski

Affiliation:	1. National Institute of Oncology, Budapest, Hungary;2. Comprehensive Cancer Center Medical University Vienna—General Hospital, Vienna, Austria;3. Tel Aviv Sourasky Medical Center, Tel Aviv, Israel;4. University of Szeged, Szeged, Hungary;5. IIIrd Medical Department with Hematology and Medical Oncology, Paracelsus Medical University, Salzburg, Austria;6. Institute of Oncology, Sarajevo, Bosnia and Herzegovina;7. Rabin Medical Center, Petach Tikva, Israel;8. Sheba Medical Center, Tel Hashomer, Israel;9. Riga Eastern Clinical University Hospital, Riga, Latvia;10. Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic;11. Postgraduate Medical Center, Warsaw, Poland;12. Oncomed Oncology Practice, Timisoara, Romania;13. IST GmbH, Mannheim, Germany

Abstract:

Keywords:
本文献已被 ScienceDirect 等数据库收录！